Two research teams said they have used Escherichia coli (E. coli) as diagnostic tools to detect liver cancer and diabetes.
In the first study, researchers at the Massachusetts Institute of Technology (MIT) and the University of California at San Diego used a harmless strain of E. coli called Nissle 1917, which is marketed as a promoter of gastrointestinal health, Xinhua news agency reported.
The researchers engineered the bacteria to produce a luminescent signal when they encounter a tumor, which will then be detected with a simple urine test.
When fed to mice by mouth, the bacteria do not accumulate in tumors all over the body, but predictably zero in on liver tumors, the researchers found. That's because the hepatic portal vein carries them from the digestive tract to the liver.
The animals that were given the engineered bacteria did not exhibit any harmful side effects, the researchers said.
With the E. coli test, the researchers said they were able to detect liver tumors larger than about one cubic millimetre, offering more sensitivity than existing imaging methods.
This kind of diagnostic could be most useful for monitoring patients after they have had a colon tumor removed because they are at risk for recurrence in the liver, according to study author Sangeeta Bhatia, a professor of health sciences and electrical engineering and computer science at the MIT.
In the second study, researchers engineered E. coli to detect biological signals in urine and, at a specific threshold, generate a visible colour change.
The researchers demonstrated their so-called bactosensors in urine samples from diabetic patients and found that they accurately and reliably detected abnormal glucose levels in urine, performing almost as well as current standard urine dipsticks.
Both papers were published in the US journal Science Translational Medicine.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
